Dropped head sign as the only symptom of myasthenia gravis

Hiroaki Yaguchi1, Asako Takei, Sanae Honma

  • 1Neurology, Kushiro Rousai Hospital. yaguchi@xa2.so-net.ne.jp

Insights

Neck extensor weakness, or dropped head sign, is uncommon in myasthenia gravis (MG). This case highlights a patient whose primary symptom was dropped head, diagnosed and treated successfully for MG.

Area of Science:

  • Neurology
  • Clinical Medicine

Background:

  • Neck extensor muscle weakness and dropped head sign are recognized symptoms in various neuromuscular disorders.
  • These clinical signs are considered relatively rare presentations of myasthenia gravis (MG).

Observation:

  • A 55-year-old male presented with subacute neck extensor muscle weakness, manifesting as a prominent dropped head sign.
  • The patient exhibited no other neurological symptoms during the entire clinical course.

Findings:

  • Diagnosis of myasthenia gravis (MG) was confirmed through a positive edrophonium test, abnormal voluntary single-fiber electromyography (vSFEMG), and elevated serum anti-acetylcholine receptor antibody levels.
  • The patient showed significant improvement in neurological symptoms following treatment with pyridostigmine.

Implications:

  • This case underscores that dropped head sign can be the sole presenting symptom of myasthenia gravis (MG).
  • It emphasizes the importance of considering MG in the differential diagnosis of isolated neck extensor weakness, even in the absence of other myasthenic signs.

Related Concept Videos

Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...